Accelerate the substitution of original research drugs, local pharmaceutical companies are constantly making efforts

With the promotion of consistency evaluation policies and the normalization of centralized procurement, domestic generic drug companies are facing increasing pressure, and a number of small and medium-sized enterprises are also being eliminated at an accelerated pace
.
However, it is worth noting that at the same time, some generic drug companies are challenging the original research drugs of multinational pharmaceutical companies to accelerate their occupation of the original research market
.
Recently, there have been reports that Shandong Lukang Pharmaceutical’s acarbose tablets are about to enter the approval process and are expected to become the company’s next blockbuster oral hypoglycemic drug
.
It is understood that acarbose is a large variety of oral hypoglycemic drugs.
In 2019, the sales in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 90%.
100 million yuan is the historical peak
.
After being included in the national procurement in 2020, the wave of price cuts caused a sharp decline in sales, leaving only about 4.
3 billion yuan, but it still occupies the forefront of non-insulin hypoglycemic drugs for oral use, and its market demand is still not to be underestimated
.
At present, with the continuous efforts of local pharmaceutical companies, domestic high-end generic drugs are accelerating the replacement of the original research drug market position
.
In addition to acarbose tablets, local pharmaceutical companies also have good news for Fulvestrant injection recently
.
On November 15, Sichuan Huiyu Pharmaceutical submitted a listing application for fulvestrant injection, and Hausen’s application for category 4 generic listings has also recently entered the approval stage
.
Data show that Fulvestrant is an estrogen receptor (ER) down-regulator, which can block the combination of estrogen and ER.
It is clinically used in anti-estrogen adjuvant therapy or recurrence during treatment or in anti-estrogen Treatment of locally advanced or metastatic breast cancer of postmenopausal ER+
.
In 2002, AstraZeneca's original research drug was approved by the FDA for marketing.
In 2018, global sales exceeded US$1 billion
.
It is worth noting that Chia Tai Tianqing Pharmaceutical Group has also submitted 4 types of generic listing applications in 2019, and was approved for the first imitation + first review in August 2020.
The market share of 2021H1 in China's public medical institutions is still Already more than 10%
.
In this regard, the industry believes that AstraZeneca, a US$1 billion injection, is becoming more and more fierce in the domestic imitation competition. .
In addition, Bayer's tedizolamide phosphate tablets and injections have also been "siege" by domestic pharmaceutical companies this year
.
On August 3, Nanjing Chia Tai Tianqing submitted an application for the 4 types of generic listing of Tedizolamide Phosphate Tablets
.
As early as June, the company has also successfully submitted an application for the four types of imitation listing of Tedizolamide Phosphate for Injection, and the relevant acceptance number is currently under review and approval
.
Public information shows that Bayer's tedizolamide phosphate tablets and injections have been approved for marketing by NMPA, and the approved indications are acute skin and skin tissue infections in adults caused by gram-positive bacteria
.
Prior to this, Beijing Fuyuan Pharmaceutical had submitted an application for the listing of Tedizolamide Phosphate Tablets in April this year, and it was the first application company for tablets
.
In addition, Yangtze River has already submitted the marketing application for Tedizolamide Phosphate for Injection as early as 2019, and Ruiyang Pharmaceuticals and Nanjing Zhengda Tianqing were added to the production this year
.
The industry predicts that as domestic pharmaceutical companies continue to be approved for listing of related drugs, it is expected to form a siege to further grab the Bayer market
.
In fact, from an overall point of view, as domestic pharmaceutical companies continue to improve their innovative strength, their development in the high-quality drug market is also accelerating.
As more and more high-quality generic drugs emerge in the industry, a large number of original drugs The market is also accelerating to be seized by local companies
.
The industry predicts that under this background, the price-compulsive effect of generic drugs may gradually appear, and a large number of imported original research drugs may join the ranks of active price reductions
.